FMX-101, 4% minocycline foam
Sponsors
Vyne Therapeutics Inc.
Conditions
Acne Vulgaris
Phase 3
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
CompletedNCT02815280
Start: 2016-05-31End: 2017-10-13Updated: 2022-01-18
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
CompletedNCT02815267
Start: 2016-05-31End: 2017-10-13Updated: 2022-01-18